A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

• Status: Active, not recruiting
• Trial end date: 2023-12-16

Summary

This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).

• Phase: Phase 2

Details

• Lead Sponsor: Genentech, Inc.
• Collaborator: Roche Pharma AG
• Treatments: Interferon beta-1a; Interferon-beta; Interferons; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Ocrelizumab; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate